No­vo Nordisk said on Wednes­day that com­pound­ing phar­ma­cies’ pro­duc­tion of its GLP-1 med­i­cine semaglu­tide had ...

Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...